MET and non-small cell lung carcinoma: The MET exon 14 skipping variant (METex14), which occurs in 2–3% of NSCLC patients, is the only MET actionable variant recognized in NSCLC [15] and confers clinical sensitivity to c-Met inhibitors such as crizotinib [16], capmatinib [17], tepotinib [18], and savolitinib [19].